Valneva's H1 Report Looms as TD Cowen's Bullish Call Collides With a Halved Share Price
Published on 08/12/2026 at 18:24 | Redaktion boerse-global.de
The French vaccine developer enters Thursday's interim results with the widest possible spread of opinions on Wall Street. TD Cowen handed Valneva a fresh "Strong-Buy" rating on Wednesday with a $12.00 price target, while Goldman Sachs maintains a "Sell" with a $4.90 target from its April downgrade. Guggenheim sits in between at $11.00.
The consensus lands at "Moderate Buy" with an average target of $11.98 — a figure that towers over the current valuation and lays bare just how fractured analyst thinking has become. Wall Street Zen and Weiss Ratings both lean bearish, adding to the split.
A Stock That Has Already Priced in Disappointment
The market's mood ahead of the print is unmistakable. Shares slipped 3.3 percent to €2.45 on Wednesday, following Tuesday's close at €2.53 — a session that itself marked an 8.58 percent jump. Even with that bounce, the stock sits roughly a third below its level at the start of the year and remains 22.73 percent under its 200-day moving average.
The first quarter did little to settle the debate: Valneva posted a loss of $0.42 per share on revenue of $35.77 million. Institutional ownership stands at roughly 11.4 percent, a modest footprint suggesting large funds have yet to embrace the story in a meaningful way.
Should investors sell immediately? Or is it worth buying Valneva?
Why TD Cowen Sees Upside
The bullish thesis rests on two pillars. First, the Lyme disease vaccine candidate LB6V, developed with Pfizer, which TD Cowen views as having "de-risked" potential. Phase 3 data from the VALOR study, released in March, showed efficacy above 70 percent in individuals aged five and older. Second, the existing travel vaccine franchise continues generating cash despite softer demand.
The pipeline offers further catalysts. On August 6, Valneva reported positive six-month antibody persistence and safety data from the Phase 2 study VLA1553-221 for its chikungunya vaccine IXCHIQ, conducted in 304 children aged one to eleven. That paves the way for a planned Phase 3 trial in the pediatric population. August also brings Phase 2b data from a controlled human infection model for the shigellosis candidate S4V2, described in media reports as the most clinically advanced vaccine against the disease.
The May Guidance Cut Still Casts a Shadow
Tuesday also saw a cluster of institutional investors — JPMorgan Chase & Co., XTX Topco Ltd and Marex Group plc among them — disclose new or adjusted positions in the stock. Such filings rarely move the needle on their own, but they signal growing attention ahead of the numbers.
The bear case remains anchored to mid-May, when Valneva trimmed its full-year 2026 product revenue guidance to €135–150 million from €145–160 million, citing weaker travel vaccine demand. That revision continues to weigh on sentiment despite the recent recovery.
The company's capital structure, disclosed on July 31, shows 189,771,237 outstanding ordinary shares and 204,239,234 net exercisable voting rights — reference points that will frame the earnings-per-share math when results land.
Thursday's report, scheduled for August 13 across multiple trading venues, will deliver the first hard evidence on whether the revenue line is stabilizing and whether the vaccine portfolio is advancing. The gap between the consensus target and the share price is so wide that the numbers will likely settle the argument — at least for now.
Ad
Valneva Stock: New Analysis - 12 August
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
